Shanghai Bode Gene Development Co., Ltd., established on 1998-03-22, Business scope includes bioengineering,Technology transfer in the field of genetic engineering expertise,technology development,technical consulting,Technical services and manufacture of related reagents and equipment,Sales;Bioengineering and Genetic Engineering Products,electronics,Chemical Products(In addition to dangerous goods)import and export business. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland.

In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. At Takeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer. They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.

Wilmar (Shanghai) Biotechnology R&D Center Co., Ltd., established on 2002-12-10, The business scope includes research and development of enzymes and enzyme preparations and application technologies,Research and development of biopesticide products,Processing of edible oil and other fats and oils,R&D of Applied Technology,plant,Research and development of deep processing technology of agricultural and sideline products and related products,food additives,Food Safety and Other Related Foods,Beverage research and development,Research and development of bioenergy technology and related products,Transfer of own technological achievements,And provide technical consultation and services related to the above business;Provide services for group investment companies and affiliated companies(rental oil tank,storehouse,office building,Industrial Facility Maintenance,sewage treatment,Logistic support, etc.)and related management.[Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

BioMarck Pharmaceuticals, Ltd. is a privately owned biopharmaceutical company dedicated to the discovery and development of new drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and a Phase 2 study of the efficacy of BIO-11006 in COPD patients. Data from the Phase 2 study demonstrated proof-of-concept of BIO-11006. BioMarck licensed its technology on a worldwide exclusive basis from North Carolina State University, based on the work of Kenneth B. Adler, Ph.D., Professor of Cell Biology, and his co-workers.

Novozymes is a world leader in bioinnovation. Novozymes works with its partners to innovate new solutions and rethink industries around the world. Novozymes' industrial enzymes, microorganisms, biopolymers, and other proteins allow its customers to achieve more efficient use of raw materials, reduce energy consumption, replace traditional chemicals with more sustainable alternatives, and offer higher-quality products. Novozymes rethinks everyday products every day.

Ascendis Pharma GmbH engages in research and development related to the administration of bioactive substances by cleavable linkers, as well as related activities. The company is headquartered in Heidelberg, Germany.

Wuhu Fumin Bio-Pharmaceutical Co., Ltd., established on 2013-07-15, Business scope includes biomedicine,Chemical raw materials and products(In addition to dangerous goods)research and development(In addition to production);Production of Glycerophosphatidylcholine(Except for pre-licensing);calcium phosphate,Potassium Chloride Sales(The above scope except hazardous chemicals);API R&D(In addition to production)and related technical advice,technology transfer,Technical Services;Self-operated and agent import and export of various commodities and technologies(Except for commodities and technologies that the state restricts the company to operate or prohibits the import and export of),Phosphatidylserine Production,Sales(Except for pre-licensing).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Tianjin Institute of Pharmaceutical Research Co., Ltd. engages in the in the development of various new products such as innovative drugs, generic drugs, new preparations, traditional Chinese medicines, and biological drugs with particular emphasis on the engineering and industrialization of new technologies to meet drug registration requirements. The company was founded in 1959 and is headquartered in Tianjin, China.

Shanghai Institutes for Biological Sciences CAS is a private company headquartered in Shanghai, China, that operates as researching agency.

Part of BioNTech SE, BioNTech RNA Pharmaceuticals GmbH is a company headquartered in Mainz, Germany, that develops immunotherapies to revolutionize the treatment of cancer and other diseases.

Laboratorios Silanes SA de CV manufactures and sells pharmaceutical products. The company engages in the development of pharmaceuticals. It offers various prescription products in therapeutic areas, such as multivitamins, cardiovascular diseases, diabetes, and anti-inflammatory medicines. The company was founded in 1943 and is headquartered in Mexico City, Mexico.

Danisco US, Inc. manufactures synthetic resins, synthetic rubbers and industrial chemicals. The company is headquartered in Wilmington, DE.

Fidia Farmaceutici SpA manufactures pharmaceutical products. The firm's platform technology level is the chemical modification, development, and manufacturing of state-of-the-art pharmaceuticals and medical devices based on hyaluronan covering therapeutic categories. The company was founded in 1946 and is headquartered in Abano Terme, Italy.

Suntory Holdings Ltd. operates as a holding company with interests in the production and distribution of alcoholic and non-alcoholic beverages, health, beauty, and processed food products. Its services include formulation and promotion of group wide management strategies and corporate functions; sale of alcoholic beverages such as whiskey, beer, and wine; soft drinks; and other beverages such as tea and canned coffee. The company was founded by Shinjiro Torii in 1899 and is headquartered in Osaka, Japan.

Shandong Xiwang Food Co., Ltd., established on 2007-04-12, Business scope includes production,sell cooking oil,Crystalline glucose,fructose,fructose,corn starch,dextrin,high maltose syrup,Oligosaccharides,beer syrup,Starch sugar series products,creamer,yellow powder,germ,fiber,crude protein,Lysine,glutamic acid,amino acid,sodium glutamate,monosodium glutamate,fructose syrup,high fructose syrup,Sorbitol,modified starch,non-dairy creamer,plastic products,Healthy food,food additives;sell sugar,Feed and feed ingredients,Various edible oils,non-staple food,snacks;Wholesale and retail of prepackaged food.General cargo.Import and export of goods within the scope of filing.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

J-Oil Mills, Inc. engages in the production, processing, and sale of fats and oil products. It operates through the following segments: Oils & Fats, Processed Products, Foodstuff & Fine Materials, and Others. The Oils & Fats segment supplies household and professional-use oils & fats, and oilseed meals. The Processed Products segment handles margarines, shortening, and powdered oils & fats. The Foodstuff & Fine Materials segment covers starch and chemical business promotions. The Others segment engages in the business of real estate leasing services. The company was founded on April 1, 2002 and is headquartered in Tokyo, Japan.

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.